Клиническое значение определения биомаркера крови ST2 у больных с хронической сердечной недостаточностью

Алиева А.М., Пинчук Т.В., Алмазова И.И., Эттингер О.А., Валиев Р.К., Батов М.А., Никитин И.Г. Клиническое значение определения биомаркера крови ST2 у больных с хронической сердечной недостаточностью. Consilium Medicum. 2021; 23 (6): 522–526. DOI: 10.26442/20751753.2021.6.200606

________________________________________________

Alieva AM, Pinchuk TV, Almazova II, Ettinger OA, Valiev RK, Batov MA, Nikitin IG. Сlinical value of blood biomarker ST2 in patients with chronic heart failure. Consilium Medicum. 2021; 23 (6): 522–526.
DOI: 10.26442/20751753.2021.6.200606

Читать PDF

Аннотация

Стимулирующий фактор роста, экспрессируемый геном 2 (ST2), и натрийуретические пептиды (BNP и NT-proBNP) отражают течение двух разных, но пересекающихся биологических процессов, поэтому маркеры могут предоставить дополнительную информацию о состоянии пациента. Будучи маркером гемодинамической нестабильности и растяжения кардиомиоцитов, NT-proBNP/BNP больше подходит для выявления хронической сердечной недостаточности, но прогностический потенциал этого маркера недостаточен для оценки возможности повторной госпитализации в течение 30 дней, а также других сердечно-сосудистых осложнений (ССО). ST2 является наиболее сильным и клинически значимым прогностическим маркером кумулятивных сердечно-сосудистых событий и смертности. Использование новых высокоспецифичных кардиобиомаркеров позволит прогнозировать развитие ССО с высокой степенью прогностической ценности и, следовательно, позволит профилактически назначать соответствующую патогенетическую терапию, направленную на улучшение качества жизни пациентов, снижение смертности от сердечно-сосудистых заболеваний и сокращение экономических затрат государства на лечение сердечной недостаточности и ССО.

Ключевые слова: хроническая сердечная недостаточность, клиническое значение ST2, натрийуретические пептиды, биомаркеры, прогноз

________________________________________________

Stimulating growth factor expressed by gene 2 (ST2) and natriuretic peptides (BNP and NT-proBNP) reflect the flow of two different, but intersecting biological processes, so the markers provide independent and complementary information on the patient’s condition. Being markers of hemodynamic instability or stretching of cardiomyocytes NT-proBNP/BNP is more suitable for detecting chronic heart failure, but this is not enough to rehospitalize patients for 30 days with the predictive qualities of this marker. ST2 is the strongest and clinically significant prognostic marker of cumulative cardiovascular events and mortality. The use of new highly specific cardiobiomarkers will make it possible to predict the development of cardiovascular complications with a high degree of predictive value, and therefore will allow prophylactically prescribing appropriate pathogenetic therapy aimed at improving the quality of life of patients, reducing mortality from cardiovascular diseases and reducing the economic costs of the state for treating heart failure and cardiovascular complications.

Keywords: chronic heart failure, clinical significance of ST2, natriuretic peptides, biomarkers, forecast

Полный текст

Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.

Список литературы

1. Pascual-Figal DA, Lax A, Perez-Martinez MT, et al. Clinical relevance of sST2 in cardiac diseases. Clin Chem Lab Med. 2016;54(1):29-35. DOI:10.1515/cclm-2015-0074
2. Januzzi JL Jr, Ahmad T, Mulder H, et al. Natriuretic Peptide Response and Outcomes in Chronic Heart Failure With Reduced Ejection Fraction. J Am Coll Cardiol. 2019;74(9):1205-17. DOI:10.1016/j.jacc.2019.06.055
3. Ciccone MM, Cortese F, Gesualdo M, et al. A Novel Cardiac Bio-Marker: ST2: A Review. Molecules. 2013;18(12):15314-28. DOI:10.3390/molecules181215314
4. Sanada S, Hakuno D, Higgins LJ, et al. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest. 2007;117:1538-49. DOI:10.1172/JCI30634
5. Januzzi JL Jr. ST2 as a Cardiovascular Risk Biomarker: From the Bench to the Bedside. J Cardiovasc Transl Res. 2013;6(4):493-500. DOI:10.1007/s12265-013-9459-y
6. Nadar SK, Shaikh MM. Biomarkers in Routine Heart Failure Clinical Care. Card Fail Rev. 2019;5(1):50-6. DOI:10.15420/cfr.2018.27.2
7. Mueller T, Jaffe AS. Soluble ST2: Analytical considerations. Am J Cardiol. 2015;115(7 Suppl):8B-21B. DOI:10.1016/j.amjcard.2015.01.035
8. Boisot S, Beede J, Isakson S, et al. Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure. J Card Fail. 2008;14(9):732-8. DOI:10.1016/j.cardfail.2008.06.415
9. Mueller T, Dieplinger B, Gegenhuber A, et al. Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure. Clin Chem. 2008;54(4):752-6.DOI:10.1373/clinchem.2007.096560
10. Копьева К.В., Гракова Е.В., Тепляков А.Т. Новые маркеры сердечной недостаточности: значение для диагностики и прогнозирования NT-proBNP и интерлейкиновых рецепторов – членов семейства ST2. Комплексные проблемы сердечно-сосудистых заболеваний. 2018;7(1):94-101 [Kopeva KV, Grakova EV, Tepliakov AT. Novye markery serdechnoi nedostatochnosti: znachenie dlia diagnostiki i prognozirovaniia NT-proBNP i interleikinovykh retseptorov – chlenov semeistva ST2. Kompleksnye problemy serdechno- sosudistykh zabolevanii. 2018;7(1):94-101 (in Russian)]. DOI:10.17802/2306-1278-2018-7-1-94-101
11. Lupón J, de Antonio M, Vila J, et al. Development of a novel heart failure risk tool: The Barcelona Bio-Heart Failure Risk Calculator (BCN bio-HF Calculator). PLoS One. 2014;9(1):e85466. DOI:10.1371/journal.pone.0085466
12. Emdin M, Aimo A, Vergaro G, et al. sST2 predicts outcome in chronic heart failure beyond NT-proBNP and high-sensitivity troponin T. J Am Coll Cardiol. 2018;72(19):2309-20. DOI:10.1016/j.jacc.2018.08.2165
13. Gaggin HK, Motiwala S, Bhardwaj A, et al. Soluble concentrations of the interleukin receptor family member ST2 and β-blocker therapy in chronic heart failure. Circ Heart Fail. 2013;6(6):1206-13. DOI:10.1161/CIRCHEARTFAILURE.113.000457
14. Dudek M, Kałużna-Oleksy M, Migaj J, Straburzyńska-Migaj E. Clinical value of soluble ST2 in cardiology. Adv Clin Exp Med. 2020;29(10):1205-10. DOI:10.17219/acem/126049
15. Coronado MJ, Bruno KA, Blauwet LA, et al. Elevated sera sST2 is associated with heart failure in men ≤50 years old with myocarditis. J Am Heart Assoc. 2019;8(2):e008968. DOI:10.1161/JAHA.118.008968
16. Farcaş AD, Anton FP, Goidescu CM, et al. Serum soluble ST2 and diastolic dysfunction in hypertensive patients. Dis Markers. 2017;2714095. DOI:10.1155/2017/2714095
17. Chen C, Qu X, Gao Z, et al. Soluble ST2 in patients with nonvalvular atrial fibrillation and prediction of heart failure. Int Heart J. 2018;59(1):58-63. DOI:10.1536/ihj.16-520
18. Okar S, Kaypakli O, Şahin DY, Koç M. Fibrosis marker soluble ST2 predicts atrial fibrillation recurrence after cryoballoon catheter ablation of nonvalvular paroxysmal atrial fibrillation. Korean Circ J. 2018;48(10):920-9. DOI:10.4070/kcj.2018.0047
19. Ibrahim NE, Lyass A, Gaggin HK, et al. Predicting new-onset HF in patients undergoing coronary or peripheral angiography: Results from the Catheter Sampled Blood Archive in Cardiovascular Diseases (CASABLANCA) study. ESC Heart Fail. 2018;5(3):240-8. DOI:10.1002/ehf2.12268
20. Patel DM, Thiessen-Philbrook H, Brown JR, et al. Association of plasma soluble ST2 and galectin 3 with cardiovascular events and mortality following cardiac surgery. Am Heart J. 2020;220:253-63. DOI:10.1016/j.ahj.2019.11.014
21. Lupón J, de Antonio M, Galán A, et al. Combined use of the novel biomarkers high sensitivity troponin T and ST2 for heart failure risk stratification vs conventional assessment. Mayo Clin Proc. 2013;88(3):234-43. DOI:10.1016/j.mayocp.2012.09.016:234-43
22. Anand IS, Rector TS, Kuskowski M, et al. Prognostic Value of Soluble ST2 in the Valsartan Heart Failure Trial. Circ Heart Fail. 2014;7(3):418-26. DOI:10.1161/CIRCHEARTFAILURE.113.001036
23. Vorovich E, French B, Ky B, et al. Biomarker predictors of cardiac hospitalization in chronic heart failure: a recurrent event analysis. J Card Fail. 2014;20(8):569-76. DOI:10.1016/j.cardfail.2014.05.013
24. Ahmad T, Fiuzat M, Neely B, et al. Biomarkers of myocardial stress and fibrosis as predictors of mode of death in patients with chronic heart failure. JACC Heart Fail. 2014;2:260-8. DOI:10.1016/j.jchf.2013.12.004
25. Yancy CW, Jessup M, Bozkurt B, et al. American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62(16):e147-239. DOI:10.1016/j.jacc.2013.05.019
26. Gaggin HK, Szymonifka J, Bhardwaj A, et al. Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and highly-sensitive troponin T measurements in patients with chronicheart failure. JACC Heart Fail. 2014;2(1):65-72. DOI:10.1016/j.jchf.2013.10.005
27. Caselli C, D’Amico A, Ragusa R, et al. IL-33/ST2 pathway and classical cytokines in end-stage heart failure patients submitted to left ventricular assist device support: a paradoxic role for inflammatory mediators? Mediators Inflamm. 2013;2013:498703. DOI:10.1155/2013/498703
28. Zilinski JL, Shah RV, Gaggin HK, et al. Measurement of multiple biomarkers in advanced stage heart failure patients treated with pulmonary artery catheter guided therapy. Crit Care. 2012;16(4):R135. DOI:10.1186/cc11440
29. Dieplinger B, Mueller T. Soluble ST2 in heart failure. Clin Chim Acta. 2015;443:57-70.
DOI:10.1016/j.cca.2014.09.021

________________________________________________

1. Pascual-Figal DA, Lax A, Perez-Martinez MT, et al. Clinical relevance of sST2 in cardiac diseases. Clin Chem Lab Med. 2016;54(1):29-35. DOI:10.1515/cclm-2015-0074
2. Januzzi JL Jr, Ahmad T, Mulder H, et al. Natriuretic Peptide Response and Outcomes in Chronic Heart Failure With Reduced Ejection Fraction. J Am Coll Cardiol. 2019;74(9):1205-17. DOI:10.1016/j.jacc.2019.06.055
3. Ciccone MM, Cortese F, Gesualdo M, et al. A Novel Cardiac Bio-Marker: ST2: A Review. Molecules. 2013;18(12):15314-28. DOI:10.3390/molecules181215314
4. Sanada S, Hakuno D, Higgins LJ, et al. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest. 2007;117:1538-49. DOI:10.1172/JCI30634
5. Januzzi JL Jr. ST2 as a Cardiovascular Risk Biomarker: From the Bench to the Bedside. J Cardiovasc Transl Res. 2013;6(4):493-500. DOI:10.1007/s12265-013-9459-y
6. Nadar SK, Shaikh MM. Biomarkers in Routine Heart Failure Clinical Care. Card Fail Rev. 2019;5(1):50-6. DOI:10.15420/cfr.2018.27.2
7. Mueller T, Jaffe AS. Soluble ST2: Analytical considerations. Am J Cardiol. 2015;115(7 Suppl):8B-21B. DOI:10.1016/j.amjcard.2015.01.035
8. Boisot S, Beede J, Isakson S, et al. Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure. J Card Fail. 2008;14(9):732-8. DOI:10.1016/j.cardfail.2008.06.415
9. Mueller T, Dieplinger B, Gegenhuber A, et al. Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure. Clin Chem. 2008;54(4):752-6.DOI:10.1373/clinchem.2007.096560
10. Kopeva KV, Grakova EV, Tepliakov AT. Novye markery serdechnoi nedostatochnosti: znachenie dlia diagnostiki i prognozirovaniia NT-proBNP i interleikinovykh retseptorov – chlenov semeistva ST2. Kompleksnye problemy serdechno- sosudistykh zabolevanii. 2018;7(1):94-101 (in Russian) DOI:10.17802/2306-1278-2018-7-1-94-101
11. Lupón J, de Antonio M, Vila J, et al. Development of a novel heart failure risk tool: The Barcelona Bio-Heart Failure Risk Calculator (BCN bio-HF Calculator). PLoS One. 2014;9(1):e85466. DOI:10.1371/journal.pone.0085466
12. Emdin M, Aimo A, Vergaro G, et al. sST2 predicts outcome in chronic heart failure beyond NT-proBNP and high-sensitivity troponin T. J Am Coll Cardiol. 2018;72(19):2309-20. DOI:10.1016/j.jacc.2018.08.2165
13. Gaggin HK, Motiwala S, Bhardwaj A, et al. Soluble concentrations of the interleukin receptor family member ST2 and β-blocker therapy in chronic heart failure. Circ Heart Fail. 2013;6(6):1206-13. DOI:10.1161/CIRCHEARTFAILURE.113.000457
14. Dudek M, Kałużna-Oleksy M, Migaj J, Straburzyńska-Migaj E. Clinical value of soluble ST2 in cardiology. Adv Clin Exp Med. 2020;29(10):1205-10. DOI:10.17219/acem/126049
15. Coronado MJ, Bruno KA, Blauwet LA, et al. Elevated sera sST2 is associated with heart failure in men ≤50 years old with myocarditis. J Am Heart Assoc. 2019;8(2):e008968. DOI:10.1161/JAHA.118.008968
16. Farcaş AD, Anton FP, Goidescu CM, et al. Serum soluble ST2 and diastolic dysfunction in hypertensive patients. Dis Markers. 2017;2714095. DOI:10.1155/2017/2714095
17. Chen C, Qu X, Gao Z, et al. Soluble ST2 in patients with nonvalvular atrial fibrillation and prediction of heart failure. Int Heart J. 2018;59(1):58-63. DOI:10.1536/ihj.16-520
18. Okar S, Kaypakli O, Şahin DY, Koç M. Fibrosis marker soluble ST2 predicts atrial fibrillation recurrence after cryoballoon catheter ablation of nonvalvular paroxysmal atrial fibrillation. Korean Circ J. 2018;48(10):920-9. DOI:10.4070/kcj.2018.0047
19. Ibrahim NE, Lyass A, Gaggin HK, et al. Predicting new-onset HF in patients undergoing coronary or peripheral angiography: Results from the Catheter Sampled Blood Archive in Cardiovascular Diseases (CASABLANCA) study. ESC Heart Fail. 2018;5(3):240-8. DOI:10.1002/ehf2.12268
20. Patel DM, Thiessen-Philbrook H, Brown JR, et al. Association of plasma soluble ST2 and galectin 3 with cardiovascular events and mortality following cardiac surgery. Am Heart J. 2020;220:253-63. DOI:10.1016/j.ahj.2019.11.014
21. Lupón J, de Antonio M, Galán A, et al. Combined use of the novel biomarkers high sensitivity troponin T and ST2 for heart failure risk stratification vs conventional assessment. Mayo Clin Proc. 2013;88(3):234-43. DOI:10.1016/j.mayocp.2012.09.016:234-43
22. Anand IS, Rector TS, Kuskowski M, et al. Prognostic Value of Soluble ST2 in the Valsartan Heart Failure Trial. Circ Heart Fail. 2014;7(3):418-26. DOI:10.1161/CIRCHEARTFAILURE.113.001036
23. Vorovich E, French B, Ky B, et al. Biomarker predictors of cardiac hospitalization in chronic heart failure: a recurrent event analysis. J Card Fail. 2014;20(8):569-76. DOI:10.1016/j.cardfail.2014.05.013
24. Ahmad T, Fiuzat M, Neely B, et al. Biomarkers of myocardial stress and fibrosis as predictors of mode of death in patients with chronic heart failure. JACC Heart Fail. 2014;2:260-8. DOI:10.1016/j.jchf.2013.12.004
25. Yancy CW, Jessup M, Bozkurt B, et al. American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62(16):e147-239. DOI:10.1016/j.jacc.2013.05.019
26. Gaggin HK, Szymonifka J, Bhardwaj A, et al. Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and highly-sensitive troponin T measurements in patients with chronicheart failure. JACC Heart Fail. 2014;2(1):65-72. DOI:10.1016/j.jchf.2013.10.005
27. Caselli C, D’Amico A, Ragusa R, et al. IL-33/ST2 pathway and classical cytokines in end-stage heart failure patients submitted to left ventricular assist device support: a paradoxic role for inflammatory mediators? Mediators Inflamm. 2013;2013:498703. DOI:10.1155/2013/498703
28. Zilinski JL, Shah RV, Gaggin HK, et al. Measurement of multiple biomarkers in advanced stage heart failure patients treated with pulmonary artery catheter guided therapy. Crit Care. 2012;16(4):R135. DOI:10.1186/cc11440
29. Dieplinger B, Mueller T. Soluble ST2 in heart failure. Clin Chim Acta. 2015;443:57-70.
DOI:10.1016/j.cca.2014.09.021

Авторы

А.М. Алиева*1, Т.В. Пинчук1, И.И. Алмазова2, О.А. Эттингер1, Р.К. Валиев3, М.А. Батов1, И.Г. Никитин1

1 ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России, Москва, Россия;
2 ФГБУ «Национальный медицинский исследовательский центр терапии и профилактической медицины» Минздрава России, Москва, Россия;
3 ГБУЗ «Московский клинический научно-практический центр им. А.С. Логинова» Департамента здравоохранения г. Москвы, Москва, Россия
*amisha_alieva@mail.ru

________________________________________________

Amina M. Alieva*1, Tatiana V. Pinchuk1, Ilda I. Almazova2, Olga A. Ettinger1, Ramiz K. Valiev3, Maxim A. Batov1, Igor G. Nikitin1

1 Pirogov Russian National Research Medical University, Moscow, Russia;
2 National Research Center for Therapy and Preventive Medicine, Moscow, Russia;
3 Loginov Moscow Clinical Scientific and Practical Center, Moscow, Russia
*amisha_alieva@mail.ru

Назад к списку

Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.